Along with quizartinib, Daiichi Sankyo’s late-stage pipeline projects in cancer are CSF-1R/KIT/FLT3 inhibitor pexidartinib for tenosynovial giant cell tumours and Amgen-partnered anti-RANKL ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback